FDA backs cancer drug for treating MS.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D008942:Mitoxantrone / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D018579:Patient Selection; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D008942:Mitoxantrone